8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      International Survey of Thrombolytic Use for Treatment of Cardiac Arrest Due to Massive Pulmonary Embolism

      research-article
      , PharmD, MS, BCPS, BCCCP, FCCM 1, , 2 , , , PharmD, BCPS, BCCCP 3 , , PharmD, BCPS 4 , , PharmD, BCPS, BCCCP 5 , , PharmD, BCPS 6 , , PharmD, BCPS, BCCCP 7, , 8 , , PharmD, MBA, MSc, BCPS, BCCCP, FCCM 9, , 10
      Critical Care Explorations
      Wolters Kluwer Health
      cardiac arrest, massive pulmonary embolism, pulmonary embolism, thrombolytic

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Supplemental Digital Content is available in the text.

          Abstract

          Objectives:

          This survey sought to characterize the national prescribing patterns and barriers to the use of thrombolytic agents in the treatment of pulmonary embolism, with a specific focus on treatment during actual or imminent cardiac arrest.

          Design:

          A 19-question international, cross-sectional survey on thrombolytic use in pulmonary embolism was developed, validated, and administered. A multivariable logistic regression was conducted to determine factors predictive of utilization of thrombolytics in the setting of cardiac arrest secondary to pulmonary embolism.

          Setting:

          International survey study.

          Subjects:

          Physicians, pharmacists, nurses, and other healthcare professionals who were members of the Society of Critical Care Medicine.

          Interventions:

          None.

          Measurements and Main Results:

          Thrombolytic users were compared with nonusers. Respondents ( n = 272) predominately were physicians (62.1%) or pharmacists (30.5%) practicing in an academic medical center (54.8%) or community teaching setting (24.6%). Thrombolytic users ( n = 177; 66.8%) were compared with nonusers ( n = 88; 33.2%) Thrombolytic users were more likely to work in pulmonary/critical care (80.2% thrombolytic use vs 59.8%; p < 0.01) and emergency medicine (6.8% vs 3.5%; p < 0.01). Users were more likely to have an institutional guideline or policy in place pertaining to the use of thrombolytics in cardiac arrest (27.8% vs 13.6%; p < 0.01) or have a pulmonary embolism response team (38.6% vs 19.3%; p < 0.01). Lack of evidence supporting use and the risk of adverse outcomes were barriers to thrombolytic use. Working in a pulmonary/critical care environment (odds ratio, 2.36; 95% CI, 1.24–4.52) and comfort level (odds ratio, 2.77; 95% CI, 1.7–4.53) were predictive of thrombolytic use in the multivariable analysis.

          Conclusions:

          Most survey respondents used thrombolytics in the setting of cardiac arrest secondary to known or suspected pulmonary embolism. This survey study adds important data to the literature surrounding thrombolytics for pulmonary embolism as it describes thrombolytic user characteristic, barriers to use, and common prescribing practices internationally.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: not found
          • Article: not found

          British Thoracic Society guidelines for the management of suspected acute pulmonary embolism.

          (2003)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Thrombolysis during resuscitation for out-of-hospital cardiac arrest.

            Approximately 70% of persons who have an out-of-hospital cardiac arrest have underlying acute myocardial infarction or pulmonary embolism. Therefore, thrombolysis during cardiopulmonary resuscitation may improve survival. In a double-blind, multicenter trial, we randomly assigned adult patients with witnessed out-of-hospital cardiac arrest to receive tenecteplase or placebo during cardiopulmonary resuscitation. Adjunctive heparin or aspirin was not used. The primary end point was 30-day survival; the secondary end points were hospital admission, return of spontaneous circulation, 24-hour survival, survival to hospital discharge, and neurologic outcome. After blinded review of data from the first 443 patients, the data and safety monitoring board recommended discontinuation of enrollment of asystolic patients because of low survival, and the protocol was amended. Subsequently, the trial was terminated prematurely for futility after enrolling a total of 1050 patients. Tenecteplase was administered to 525 patients and placebo to 525 patients; the two treatment groups had similar clinical profiles. We did not detect any significant differences between tenecteplase and placebo in the primary end point of 30-day survival (14.7% vs. 17.0%; P=0.36; relative risk, 0.87; 95% confidence interval, 0.65 to 1.15) or in the secondary end points of hospital admission (53.5% vs. 55.0%, P=0.67), return of spontaneous circulation (55.0% vs. 54.6%, P=0.96), 24-hour survival (30.6% vs. 33.3%, P=0.39), survival to hospital discharge (15.1% vs. 17.5%, P=0.33), or neurologic outcome (P=0.69). There were more intracranial hemorrhages in the tenecteplase group. When tenecteplase was used without adjunctive antithrombotic therapy during advanced life support for out-of-hospital cardiac arrest, we did not detect an improvement in outcome, in comparison with placebo. (ClinicalTrials.gov number, NCT00157261.) 2008 Massachusetts Medical Society
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism.

                Bookmark

                Author and article information

                Journal
                Crit Care Explor
                Crit Care Explor
                CC9
                Critical Care Explorations
                Wolters Kluwer Health
                2639-8028
                June 2020
                09 June 2020
                : 2
                : 6
                : e0132
                Affiliations
                [1 ]Department of Pharmacy, Loyola University Medical Center, Maywood, IL.
                [2 ]Department of Emergency Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL.
                [3 ]Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX.
                [4 ]Department of Pharmacy, Beaumont Hospital, Royal Oak, MI.
                [5 ]Department of Pharmacy, Erlanger Health System, Chattanooga, TN.
                [6 ]Department of Pharmacy, The University of Chicago Medicine, Chicago, IL.
                [7 ]Department of Pharmacy, Froedtert & the Medical College of Wisconsin, Milwaukee, WI.
                [8 ]Department of Pharmacy Practice, Concordia University Wisconsin School of Pharmacy, Mequon, WI.
                [9 ]Department of Pharmacy, Rush University Medical Center, Chicago, IL.
                [10 ]Department of Internal Medicine, Rush Medical College, Chicago, IL.
                Author notes
                For information regarding this article, E-mail: mrech@ 123456lumc.edu
                Article
                00005
                10.1097/CCE.0000000000000132
                7314323
                f4568f4f-2e51-4685-80df-82d6a87b6131
                Copyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.

                This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

                This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

                History
                Categories
                Original Clinical Report
                Custom metadata
                TRUE
                T

                cardiac arrest,massive pulmonary embolism,pulmonary embolism,thrombolytic

                Comments

                Comment on this article